NuvoAir Home Platform Classified as Class Im Medical Device
Aug 21, 2020 07:00 am | Joana Carvalho, PhD
The NuvoAir Home platform, NuvoAir’s respiratory support system for patients with lung diseases such as cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF), has been classified as a Class Im Medical Device. Devices falling in the Class I category are those that have a low-to-moderate risk of having a negative impact on human health. Within this […]
The post NuvoAir Home Platform Classified as Class Im Medical Device appeared first on Cystic Fibrosis News Today. |
|
EveryLife Foundation Launches Scholarship Fund for Rare Disease Community in US
Aug 20, 2020 09:00 am | Mary Chapman
The EveryLife Foundation for Rare Diseases has launched a scholarship fund in the U.S. to support individuals with rare disorders who are pursuing personal goals through training and education. The initial phase of the five-year, $1-million #RAREis Scholarship Fund will include 32 scholarships — each totaling $5,000 — to be used for college or training […]
The post EveryLife Foundation Launches Scholarship Fund for Rare Disease Community in US appeared first on Cystic Fibrosis News Today. |
|
FDA Grants Orphan Drug Designation to KB407, Potential Gene Therapy for CF
Aug 20, 2020 07:00 am | Joana Carvalho, PhD
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to KB407, Krystal Biotech’s potential inhaled gene therapy for the treatment of cystic fibrosis (CF). “We are pleased to receive Orphan Drug Designation for KB407 to treat cystic fibrosis as this is an important step forward in our efforts to address […]
The post FDA Grants Orphan Drug Designation to KB407, Potential Gene Therapy for CF appeared first on Cystic Fibrosis News Today. |
|
|
No hay comentarios:
Publicar un comentario